Project GAPVAC – Glioma Actively Personalized Vaccine Consortium / CIMT partner

Basic data

Acronym:
GAPVAC
Title:
Glioma Actively Personalized Vaccine Consortium / CIMT partner
Duration:
01/11/2012 to 01/11/2016
Abstract / short description:
The Glioma Actively Personalized VAccine Consortium (GAPVAC) is the first EU-funded initiative aimed at clinically developing biomarker-guided actively personalized vaccines (APVACs) to treat cancer patients.
Keywords:
Glioblastoma
immunotherapy
Immuntherapie
Peptide vaccine

Involved staff

Managers

Faculty of Medicine
University of Tübingen

Contact persons

Faculty of Medicine
University of Tübingen
Immunology
Interfaculty Institute for Cell Biology (IFIZ), Interfaculty Institutes

Local organizational units

Immunology
Interfaculty Institute for Cell Biology (IFIZ)
Interfaculty Institutes

Funders

Brüssel, Belgium
Help

will be deleted permanently. This cannot be undone.